Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

FDA has granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.

September 11, 2026

Vol.52 No.33

Podcast

Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”

In last week’s issue of The Cancer Letter, Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial.

August 19, 2026

Clinical Guest Editorial

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

A patient recently asked me a question I suspect many thoracic surgeons will soon be hearing.

August 07, 2026

Vol.52 No.31

By Raja M. Flores

Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

YOU MAY BE INTERESTED IN

When did stage 3B lung cancer become “early stage”?

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

Renew today!

Subscriber content

Never miss an issue!

Login